A Scalable Method For Squalenoylation And Assembly Of Multifunctional ⁶⁴Cu-Labeled Squalenoylated Gemcitabine Nanoparticles

Samantha T. Tucci, Jai W. Seo, Hamilton Kakwere, Azadeh Kheirolomoom, Elizabeth S. Ingham, Lisa M. Mahakian, Sarah Tam, Spencer Tumbale, Mo Baikoghli, Holland Cheng, Katherine W. Ferrara

Supplemental Materials

Figure S1. NMR of TBDMS-Gem (7).

Figure S3. NMR of SqGem (8).

Figure S4. SqGem-CholPEG and SqGem-CholPEG-Chol NPs size and morphology.

Figure S5. Morphology of SqGem-CholPEG and SqGem-CholPEG-Chol NPs after cooling.

Figure S6. Efficacy of SqGem-CholPEG NPs compared to gemcitabine after 24h incubation.

Figure S7. NMR of SqNHS (8).

Figure S8. MALDI of SqNHS (8).

Figure S9. MALDI of SqNOTA (10).

Table S1. Biodistribution of SqNOTA and SqNOTA-SqGem NPs after 4h of circulation.

Table S2. Pharmacokinetics of SqNOTA and SqNOTA-SqGem NPs after 4h of circulation.

Figure S2. ESI-MS of TBDMS-Gem (7) squalenoylated TBDMS-protected gemcitabine, and SqGem (8)



Figure S1. NMR of TBDMS-Gem (7) in CDCl₃ at 800 MHz.



Figure S2. ESI-MS of TBDMS-protected gemcitabine (7) with an exact mass of 491.24 (A), squalenoylated TBDMS-protected gemcitabine (8) with an exact mass of 873.57 (B), and of SqGem (9) with an exact mass of 645.41 (C).



Figure S3. NMR of SqGem (8) in CDCl₃ at 800 MHz.



Figure S4. SqGem-CholPEG and SqGem-CholPEG-Chol NPs size and morphology. SqGem-CholPEG NPs with and without cholesterol (Chol) were evaluated at 4°C using dynamic light scatter to measure size and polydispersity index (PDI) (A) and transmission electron microscopy (B).



Figure S5. Morphology of SqGem-CholPEG and SqGem-CholPEG-Chol NPs after cooling. Transmission electron microscopy images of SqGem-CholPEG NPs with (A) and without 20% Chol (B) were kept at 4°C for 4h and then warmed to room temperature.



Figure S6. Efficacy of SqGem-CholPEG NPs compared to gemcitabine. Dose response curves of SqGem-CholPEG NPs and gemcitabine in monolayer cultured KPC cells after 24h continuous drug incubation.



Figure S7. NMR of SqNHS (8) in CDCl₃ at 800 MHz.



Figure S8. MALDI of SqNHS (8).



Figure S9. MALDI of SqNOTA (10).

	SqNOTA		SqNOTA-SqGem NPs			
	Average	Standard Deviation	Average	Standard Deviation	P value	
Blood	0.500	0.092	1.554	0.073	0.0001	****
Urine	2.735	1.587	1.991	0.130	0.4185	n.s.
Heart	0.304	0.026	0.978	0.076	0.0001	***
Lungs	0.904	0.209	2.187	0.565	0.0145	*
Liver	11.315	2.059	13.0641	1.046	0.1973	n.s.
Spleen	1.207	0.180	4.026	0.432	0.0003	***
Pancreas	0.314	0.056	0.731	0.064	< 0.0001	****
Kidneys	1.791	0.440	2.647	0.186	0.0227	*
Stomach	0.928	0.410	1.293	0.592	0.2831	n.s.
Intestine	8.946	3.399	7.136	2.137	0.4083	n.s.
Muscle	0.122	0.020	0.206	0.022	0.0013	**
Bone	0.272	0.036	0.485	0.062	0.0022	*
Brain	0.296	0.045	0.337	0.026	0.1746	n.s.
Whole body (%ID)	52.84	1.418	72.92	3.444	0.0004	***

* p< 0.05, ** p < 0.01, *** p < 0.005, **** p<0.0001

Table S1. Biodistribution of SqNOTA and SqNOTA-SqGem NPs after 4h of circulation. Unit is percent injected dose per gram unless otherwise noted. Statistical analysis by multiple comparisons.

Time (minutes)	SqNOTA		SqNOTA-SqGem NPs			
	Average	Standard Deviation	Average	Standard Deviation	P value	
2.5	35.851	1.843	44.809	6.310	0.0608	n.s.
3.5	33.699	4.423	39.543	4.171	0.1031	n.s.
4.5	33.344	4.374	35.972	3.731	0.3967	n.s.
7.5	28.870	3.046	33.600	3.689	0.0970	n.s.
12.5	24.557	3.123	29.072	2.212	0.0610	n.s.
17.5	21.372	4.081	26.377	2.222	0.0881	n.s.
25	17.264	3.446	22.310	1.495	0.0536	n.s.
240	0.572	0.278	1.839	0.260	0.0006	***

* p< 0.05, ** p < 0.01, *** p < 0.005, **** p<0.0001

Table S2. Pharmacokinetics of SqNOTA and SqNOTA-SqGem NPs after 4h of circulation. Unit is percent injected dose per cubic centimeter. Statistical analysis by multiple comparisons.